2021 Targeted Therapies of Lung Cancer (TTLC) Meeting - Posters-P09. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients With Lung Adenocarcinoma With EGFR Exon 20 Insertions

P09. Response to Standard Therapies and Comprehensive Genomic Analysis for Patients With Lung Adenocarcinoma With EGFR Exon 20 Insertions - PDF

Back to course

Pdf Summary

This study conducted at the Memorial Sloan Kettering Cancer Center aimed to investigate the treatment outcomes, genomic characteristics, and immunophenotypic features of patients with lung adenocarcinoma with EGFR exon 20 insertions (ex20ins). The researchers retrospectively analyzed data from 106 NSCLC patients with EGFR ex20ins and compared their clinical outcomes and pathologic features with other NSCLC patients.<br /><br />The results showed that patients with EGFR ex20ins were more likely to be Black, Asian, or have a light or no smoking history. These patients had lower tumor mutational burden (TMB) and a lower proportion of tumors with PD-L1 expression compared to unselected NSCLC and EGFR del19/L858R patients. EGFR ex20ins patients had better overall survival and longer time to treatment discontinuation for platinum chemotherapy compared to a control cohort of NSCLC patients without targetable alterations. However, there was no significant improvement in time to treatment discontinuation for immune checkpoint inhibitors.<br /><br />Based on these findings, the researchers concluded that patients with EGFR ex20ins NSCLC have improved prognosis, lower PD-L1 expression, lower TMB, and derive less benefit from immune checkpoint inhibitors compared to patients without a targetable oncogene. Therefore, there is a need to improve molecularly targeted therapies to provide greater benefit for patients with EGFR ex20ins.<br /><br />In summary, this study sheds light on the treatment outcomes and genomic characteristics of NSCLC patients with EGFR ex20ins. The findings suggest that targeted therapies may be more effective for this subgroup of patients, who have distinct molecular and immunophenotypic features. Further research and development of targeted therapies specifically tailored to EGFR ex20ins are warranted to optimize treatment options and improve patient outcomes.

Asset Subtitle

Noura Choudhury

Meta Tag

Speaker Noura Choudhury

Topic Targeted Therapies - EGFR

Keywords

Memorial Sloan Kettering Cancer Center

lung adenocarcinoma

EGFR exon 20 insertions

NSCLC patients

genomic characteristics

immunophenotypic features

treatment outcomes

tumor mutational burden

PD-L1 expression

platinum chemotherapy